Abbott’s Triclip Transcatheter Edge-To-Edge Repair System Gains the US FDA’s Approval for the Treatment of Tricuspid Regurgitation
Shots:
- The US FDA’s approval was based on the (TRILUMINATE) pivotal study that compared the safety and effectiveness of the TriClip system with medical therapy for treating severe tricuspid regurgitation patients at intermediate or higher risk for open-heart surgery
- The trial demonstrated improved TR grade from severe to moderate or less in 90% of participants that sustained for a year & 98% of them were free from major AEs at 30 days improving their quality of life
- The TriClip's TEER technology, administered via vein in the leg, repairs the tricuspid valve by clipping flaps of tissue together enabling blood flow in the correct direction without open-heart surgery
Ref: Abbott | Image: Abbott
Related News:- Abbott’s Whole Blood Rapid Test Gains the US FDA’s Clearance to Evaluate Concussion
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
